Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Interleukin-1 receptor-associated kinase 4 | ||
Ligand | BDBM639256 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | IRAK4 ADP-Glo Assay | ||
IC50 | 3.60±n/a nM | ||
Citation | Chen, Y; Masuda, E; Lamagna, C BICYCLIC INHIBITORS OF IRAK US Patent US20230391748 Publication Date 12/7/2023 | ||
More Info.: | Get all data from this article, Assay Method | ||
Interleukin-1 receptor-associated kinase 4 | |||
Name: | Interleukin-1 receptor-associated kinase 4 | ||
Synonyms: | IRAK-4 | IRAK4 | IRAK4_HUMAN | Interleukin-1 receptor-associated kinase 4 (IRAK-4) | Interleukin-1 receptor-associated kinase 4 (IRAK4) | Renal carcinoma antigen NY-REN-64 | ||
Type: | Protein | ||
Mol. Mass.: | 51519.08 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9NWZ3 | ||
Residue: | 460 | ||
Sequence: |
| ||
BDBM639256 | |||
n/a | |||
Name | BDBM639256 | ||
Synonyms: | 1-(((S)-4,4-difluoro-5-oxopyrrolidin-2-yl)methoxy)-4-(1-((1r,4S)-4-hydroxy-4-methylcyclohexyl)-1H-pyrazol-4-yl)-7-isopropoxyisoquinoline-6-carboxamide | US20230391748, Compound I-78 | ||
Type | Small organic molecule | ||
Emp. Form. | C28H33F2N5O5 | ||
Mol. Mass. | 557.5889 | ||
SMILES | CC(C)Oc1cc2c(OC[C@@H]3CC(F)(F)C(=O)N3)ncc(-c3cnn(c3)[C@H]3CC[C@](C)(O)CC3)c2cc1C(N)=O |r,wU:10.9,26.27,29.31,wD:29.32,(4.45,5.94,;3.68,4.6,;4.45,3.27,;2.14,4.6,;1.37,3.27,;2.14,1.94,;1.37,.6,;2.14,-.73,;3.68,-.73,;4.45,-2.07,;5.99,-2.07,;6.9,-3.31,;8.36,-2.84,;9.85,-3.23,;9.13,-4.17,;8.36,-1.3,;9.69,-.53,;6.9,-.82,;1.37,-2.07,;-.17,-2.07,;-.94,-.73,;-2.48,-.73,;-3.38,.51,;-4.85,.04,;-4.85,-1.5,;-3.38,-1.98,;-6.18,-2.27,;-5.78,-3.76,;-6.87,-4.85,;-8.36,-4.45,;-8.76,-5.94,;-9.85,-4.85,;-8.76,-2.96,;-7.67,-1.87,;-.17,.6,;-.94,1.94,;-.17,3.27,;-.94,4.6,;-.17,5.94,;-2.48,4.6,)| | ||
Structure |